Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Tuesday, January 15, 2008
Hard work
IMS Health estimates that in the U.S. in 2008, brand drugs valued at $17 billion are expected to go off patent, including AstraZeneca's Casodex (oncology), and GlaxoSmithKline's Requip (Parkinson's disease).
IMS Health estimates that in the U.S. in 2008, brand drugs valued at $17 billion are expected to go off patent, including AstraZeneca's Casodex (oncology), and GlaxoSmithKline's Requip (Parkinson's disease).
No comments:
Post a Comment